

ALLERGAN INC
Form 15-15D
April 17, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 333-183092

ALLERGAN, INC.
(Exact Name of Registrant as Specified in its Charter)

Morris Corporate Center
400 Interpace Parkway
Parsippany, New Jersey 07054

(862) 261-7000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

\$250,000,000 1.350% Notes due 2018

\$350,000,000 2.800% Notes due 2023

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	..
Rule 12g-4(a)(2)	..
Rule 12h-3(b)(1)(i)	..
Rule 12h-3(b)(1)(ii)	..
Rule 15d-6	x

Approximate number of holders of record as of the certification or notice date: \$250,000,000 1.350% Notes due 2018: seventy; \$350,000,000 2.800% Notes due 2023: sixty

Pursuant to the requirements of the Securities Exchange Act of 1934, Allergan, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: April 16, 2015

ALLERGAN, INC.

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: President and Chairman of the Board